On the other hand, immune-activating ligands that facilitate anti-tumor activity of CTLs, such as CXCL9 which is known to correlate with higher immune infiltrate and better prognosis in colorectal cancer (Mlecnik et al, 2010), could also be uncovered from our screening methodology. Here, CXCL9 is linked to neoplasm.